For Healthcare Professionals

Multi-Year Recurrent Pericarditis Disease Duration in Italian Patients: Clinical Outcomes After Cessation of Long-Term IL-1 Pathway Inhibition Provide Insights for Chronic Management

Increased Adoption of IL-1 Pathway Inhibition and the Steroid-Sparing Paradigm Shift: Temporal Trends in Recurrent Pericarditis Treatment from the RESONANCE Patient Registry

Efficacy, safety, and pharmacokinetics of anti-CD40 antibody abiprubart (KPL-404) in patients with rheumatoid arthritis: a phase 2, randomized, placebo-controlled, 12-week-treatment, proof-of-concept study

Rilonacept Utilization in a Steroid-Sparing Paradigm for Recurrent Pericarditis: Real-World Evidence Demonstrating Increased Adoption

Cardiac Magnetic Resonance Imaging Paralleled Recurrent Pericarditis Clinical Response to Rilonacept Treatment Over 18 Months: a RHAPSODY Subgroup Analysis

Baseline demographics and disease characteristics of patients enrolled in registry of the natural history of recurrent pericarditis in pediatric and adult patients (RESONANCE)

Absence of pericarditis recurrence in rilonacept-treated patients with COVID-19 and mRNA vaccinations: experience from phase 3 RHAPSODY long-term extension

Prolonged rilonacept treatment in RHAPSODY long-term extension provided persistent reduction of pericarditis recurrence risk​

Dose-dependent suppression of T cell-dependent antibody response in healthy volunteers by KPL-404, an anti-CD40 monoclonal antibody, supports phase 2 study in patients with rheumatoid arthritis

Neutrophil to lymphocyte ratio for tracking inflammation and recurrence in patients with recurrent pericarditis: post hoc assessment of a phase 3 trial, RHAPSODY

Real-world experience and unmet needs in the current management of recurrent pericarditis: a physician survey and medical chart review​

Safety, tolerability, pharmacokinetics, receptor occupancy, and suppression of T-cell-dependent antibody response in a phase 1 study with KPL-404, an anti-CD40 monoclonal antibody

Characterization of recurrent pericarditis in Medicare Advantage patients: disease burden, pharmacotherapy, and outcomes

Mavrilimumab improves outcomes in phase 2 trial in non-mechanically-ventilated patients with severe COVID-19 pneumonia and systemic hyperinflammation